SML0817
Pivmecillinam
≥98% (HPLC)
别名:
Amdinocillin pivoxil
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C21H33N3O5S
化学文摘社编号:
分子量:
439.57
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
EC Number:
251-276-6
MDL number:
InChI key
NPGNOVNWUSPMDP-UTEPHESZSA-N
InChI
1S/C21H33N3O5S/c1-20(2,3)19(27)29-13-28-18(26)15-21(4,5)30-17-14(16(25)24(15)17)22-12-23-10-8-6-7-9-11-23/h12,14-15,17H,6-11,13H2,1-5H3/b22-12+/t14-,15+,17-/m1/s1
SMILES string
CC1(C)[C@H](C(OCOC(C(C)(C)C)=O)=O)N2C([C@](/N=C/N3CCCCCC3)([H])[C@@]2([H])S1)=O
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D +215 to +245°, c = 1 in ethanol
color
white to beige
solubility
DMSO: 5 mg/mL, clear (warmed)
storage temp.
−20°C
Quality Level
Application
Pivmecillinam has been used to test its efficacy as a breast cancer stem cells (CSCs) targeting agent.
Biochem/physiol Actions
Pivmecillinam is a β-lactam antibiotic and a pivaloyl-containing pro-drug. It belongs to the class of amidinopenicillin. Pivmecillinam is an oral anti-microbial agent that can be considered for treating E. coli urinary tract infection (UTI).
Pivmecillinam is a gram negative antibiotic, and inhibitor of penicillin-binding protein 2 (PBP2).
Pivmecillinam is a gram negative antibiotic, and inhibitor of penicillin-binding protein 2 (PBP2). Pivmecillinam has been shown to have synergistic effects with several antibiotics including novobiocin and rifampin in gram negative bacteria.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Soichi Arakawa et al.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 13(5), 279-284 (2007-11-06)
We aimed to reveal the usefulness of and problematic points with the Criteria for evaluation of clinical efficacy of antimicrobial agents on urinary tract infection (draft fourth edition) proposed by the UTI Subcommittee of the Clinical Evaluation Guidelines Committee, Japan
Sven A Ferry et al.
Scandinavian journal of primary health care, 25(1), 49-57 (2007-03-14)
To analyse associations between symptoms and bacteriuria in uncomplicated lower urinary tract infection in women (LUTIW) and to evaluate outcome of therapy with three different regimens of pivmecillinam or placebo. Prospective, multicentre, randomized, double-blind, and placebo-controlled therapy study. Symptoms registered
Asa Sullivan et al.
Antimicrobial agents and chemotherapy, 49(1), 170-175 (2004-12-24)
The knowledge of the effects of antimicrobial agents on the normal vaginal microflora is limited. The objective of the present study was to study the ecological impact of pivmecillinam on the normal vaginal microflora. In 20 healthy women, the estimated
C-M Lokrantz et al.
Acta neurologica Scandinavica, 109(4), 297-301 (2004-03-16)
We describe the clinical and neurophysiological findings in a case of hyperammonemic encephalopathy. A 72-year-old woman taking valproate (VPA), as monotherapy for her partial epilepsy developed urinary tract infection. She was treated with pivmecillinam 600 mg daily. The following days
Maria Loose et al.
Antibiotics (Basel, Switzerland), 9(6) (2020-07-08)
Given the increasing antimicrobial resistance in urinary tract infections (UTI), alternative strategies need to be investigated. Determination of minimal inhibitory and bactericidal concentrations of essential oils from cajeput, lemongrass, tea tree, and thyme in artificial urine, revealed bactericidal activity of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持